{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:55:02Z","timestamp":1765886102234,"version":"3.37.3"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1002\/2327-6924.12519","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T12:55:13Z","timestamp":1507812913000},"page":"S43-S52","source":"Crossref","is-referenced-by-count":19,"title":["Current pharmacotherapies for obesity"],"prefix":"10.1097","volume":"29","author":[{"given":"Angela","family":"Golden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210915","first-page":"23","article-title":"Multimorbidity in a prospective cohort: Prevalence and associations with weight loss and health status in severely obese patients","volume":"3","author":"Agborsangaya","year":"2015","journal-title":"Obesity Retrieved"},{"key":"R3-5-20210915","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: An endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"R4-5-20210915","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01554.x","article-title":"Maintained intentional weight loss reduces cardiovascular outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial","volume":"14","author":"Caterson","year":"2012","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"R6-5-20210915","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1161\/CIRCULATIONAHA.111.028381","article-title":"Food and Drug Administration's obesity drug guidance document: A short history","volume":"125","author":"Colman","year":"2012","journal-title":"Circulation"},{"key":"R7-5-20210915","doi-asserted-by":"crossref","first-page":"g2646","DOI":"10.1136\/bmj.g2646","article-title":"Long term maintenance of weight loss with non\u2010surgical interventions in obese adults: Systematic review and meta\u2010analyses of randomised controlled trials","volume":"348","author":"Dombrowski","year":"2014","journal-title":"BMJ"},{"key":"R16-5-20210915","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/oby.20824","article-title":"Meta\u2010 and cost\u2010effectiveness analysis of commercial weight loss strategies","volume":"22","author":"Finkelstein","year":"2014","journal-title":"Obesity"},{"key":"R17-5-20210915","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.CIR.99.1.156","article-title":"Aminorex to fen\/phen: An epidemic foretold","volume":"99","author":"Fishman","year":"1999","journal-title":"Circulation"},{"key":"R18-5-20210915","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: Risk factors, complications and strategies for sustainable long\u2010term weight management","volume":"29","author":"Fruh","year":"2017","journal-title":"Journal of the American Association of Nurse Practitioners"},{"key":"R20-5-20210915","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"R21-5-20210915","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ijcp.12771","article-title":"Weight management in obesity\u2014past and present","volume":"70","author":"Haslam","year":"2016","journal-title":"International Journal of Clinical Practice"},{"key":"R22-5-20210915","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2125.2009.03549.x","article-title":"Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders","volume":"68","author":"Heal","year":"2009","journal-title":"British Journal of Clinical Pharmacology"},{"key":"R23-5-20210915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/179674","article-title":"Pharmacotherapies for obesity: Past, current, and future therapies","volume":"2011","author":"Ioannides\u2010Demos","year":"2011","journal-title":"Journal of Obesity"},{"key":"R24-5-20210915","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the Management of Overweight and Obesity in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"R25-5-20210915","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000000145","article-title":"Cardiovascular effects of phentermine and topiramate: A new drug combination for the treatment of obesity","volume":"32","author":"Jordan","year":"2014","journal-title":"Journal of Hypertension"},{"key":"R26-5-20210915","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse\u2010controlled release for obesity","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"R27-5-20210915","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short\u2010term phentermine administration in Korean obese people","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Medical Journal"},{"issue":"Suppl 1","key":"R28-5-20210915","first-page":"56","article-title":"Longacting glucagonlike peptide1 receptor agonists have direct access to and effects on proopiomelanocortincocaine and amphetaminestimulated transcript neurons in the mouse hypothalamus.","volume":"7","author":"Knudsen","year":"2016","journal-title":""},{"key":"R29-5-20210915","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double\u2010blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet (London, England"},{"key":"R30-5-20210915","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/2040622314522848","article-title":"Pharmacotherapy for obesity: Novel agents and paradigms","volume":"5","author":"Manning","year":"2014","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"R31-5-20210915","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"R32-5-20210915","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1517\/14740330903321485","article-title":"Orlistat: Current status in clinical therapeutics","volume":"8","author":"McClendon","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"key":"R33-5-20210915","first-page":"1249","article-title":"Counseling for physical activity in overweight and obese patients","volume":"67","author":"McInnis","year":"2003","journal-title":"American Family Physician"},{"key":"R34-5-20210915","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP\u20101 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"R35-5-20210915","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/00325481.2016.1178590","article-title":"Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia","volume":"128","author":"Nesto","year":"2016","journal-title":"Postgraduate Medicine"},{"key":"R37-5-20210915","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/2327-6924.12504","article-title":"Biology of obesity and weight regain: Implications for clinical practice","volume":"29","author":"Rogge","year":"2017","journal-title":"Journal of the American Association of Nurse Practitioners"},{"key":"R38-5-20210915","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pop.2009.01.009","article-title":"Comorbidities of obesity","volume":"36","author":"Schelbert","year":"2009","journal-title":"Primary Care"},{"key":"R39-5-20210915","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP\u20101 receptor agonist liraglutide\u2010dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"R40-5-20210915","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"R41-5-20210915","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"R42-5-20210915","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obesity Facts"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01741002-201709001-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:35:06Z","timestamp":1631712906000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201709001-00005"}},"subtitle":["A practical perspective"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":30,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12519","relation":{},"ISSN":["2327-6924"],"issn-type":[{"type":"print","value":"2327-6924"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}